BioPharma

02 September, 2026 | Wednesday | News

Astellas Reaches US Government Agreement to Lower Medicaid Drug Prices, Strengthen Medicine Supply Chain

 Agreement supports commitment to patient access, affordability and innovation – Astellas Pharma Inc. announced that it has reached an agreement with the U.S. government that reflects our commitment...

Lab

26 August, 2026 | Wednesday | News

Thermo Fisher Launches First Orbitrap Isora Mass Spectrometers for Molecular-Level Isotope Analysis

New Orbitrap Isora workflow integrates mass spectrometry, Vanquish Duo UHPLC System and Isotope Discoverer Software to bring molecular-level isotope ratio analysis to more researchers worldwide Key highlights:...

BioTech

01 September, 2026 | Tuesday | News

Thermo Fisher Strengthens China Focus as Biopharma Innovation Gains Global Momentum

Thermo Fisher Scientific is reinforcing its commitment to China as the country emerges as an increasingly important source of global biopharmaceutical innovation, with Chairman and CEO Marc Casper highlighting ...

Contract Services

01 September, 2026 | Tuesday | News

WuXi AppTec Raises 2026 Interim Dividend to RMB 1.51 Billion Amid Global CRDMO Expansion

WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announces the distribution of its 2026 interim cas...

Consumer Health

01 September, 2026 | Tuesday | News

Ascletis Doses First Patient in Global Phase III Programme for Oral GLP-1 Obesity Drug ASC30

- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada.  - Global Phase III clinical program to ...

Medtech

01 September, 2026 | Tuesday | News

SIBIONICS Showcases AI-Powered GS3 Glucose Monitoring, Advances Integrated Diabetes Care at Melbourne Congress

SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbourne from 18–21 August. Through Booth #1, a scienti...

Cell & Gene

02 September, 2026 | Wednesday | News

US FDA Grants Fast Track Designation to T-MAXIMUM’s Allogeneic CAR-T Therapy for Recurrent Glioblastoma

T-MAXIMUM PHARMACEUTICAL Inc. ("T-MAXIMUM") announced that its investigational allogeneic CAR-T cell therapy MT027 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) fo...


Biopharma APAC Infomercial

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close